The Medicine Maker: The New Partnership Playbook

Partnerships have long been central to biotech and biopharma development, but the way companies work with external providers is changing. As programs become more complex, many organizations are looking for partners who can contribute specialist expertise, support multiple stages of development, and help manage risk across discovery, manufacturing, regulatory strategy, and commercialization.

For Biopharma Vital Signs, we asked industry leaders for their views on the state of biotech and biopharma today – including the trends shaping development, the pressure points slowing progress, and the practical challenges companies are navigating as programs advance.

How are partnership models changing across the biopharma ecosystem?

Gavin Murdoch, SVP of Commercial Strategy, Abzena

The growing technical diversity and complexity of newer modalities has made it virtually impossible for any single company, CRO, or CDMO to master every discipline. The era of the generalist is over. To advance science and serve patients faster, organizations must identify their strengths and address their gaps.

Partnership models now span a wide spectrum, from loose referral networks and defined role-and-responsibility agreements to partial ownership, licensing arrangements, and more closely coordinated development models from discovery through to patient delivery. Rather than stitching together fragmented solutions, companies are increasingly looking for continuity across the development journey, reducing project handoff risk, compressing timelines, and maintaining quality from early development through commercial supply.

Highly specialized niche providers with focused expertise in areas like cell discovery or fill/finish still play an important role. When properly orchestrated, these partnerships can create faster, higher-quality outcomes for patients.

Click here to access the full article

The post The Medicine Maker: The New Partnership Playbook appeared first on Abzena.